Suppr超能文献

术前纤维蛋白原与原发性肝癌患者的临床生存相关,并通过PTEN/AKT/mTOR途径促进肝癌转移。

Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the PTEN/AKT/mTOR pathway.

作者信息

Qian Xuemeng, Cai Jiajing, Qi Qi, Han Jia, Zhu Xinfang, Xia Rong, Zhang Qi

机构信息

Department of Transfusion Medicine, Huashan Hospital, Fudan University, Shanghai, China.

出版信息

Heliyon. 2023 May 25;9(6):e16696. doi: 10.1016/j.heliyon.2023.e16696. eCollection 2023 Jun.

Abstract

AIM

Hyperfibrinogenemia had been widely observed in various cancer patients, however, whether fibrinogen (FIB) influences the survival outcome of patients with primary liver cancer (PLC) remains unknown. This study was aimed to evaluate the predictive value of preoperative FIB in the survival outcome of PLC patients and explore the possible mechanism.

METHODS

Retrospective study was performed in PLC patients who underwent hepatectomy. Logistic regression analysis was used to explore the independent risk factors of the overall survival (OS) of PLC patients. The predictive value of FIB for the survival outcome was analyzed by Kaplan-Meier method, receiver operating characteristic curve and Cox proportional hazard model combined with B-splines. Hepatoma cell migration and invasion were detected by wound healing assay and Transwell assay, protein expression was measured by Western blot. mTOR inhibitor and PTEN overexpression plasmid were used to confirm the involvement of the PTEN/AKT/mTOR pathway during FIB treatment.

RESULTS

Preoperative FIB was confirmed to be related with the OS in PLC patients, higher FIB (>2.5 g/L) indicated higher hazard ratio. Meanwhile, FIB could promote hepatoma cell migration and invasion through the activation of AKT/mTOR pathway and epithelial-mesenchymal transformation (EMT). Moreover, the promotion of FIB on cell migration and invasion could be inhibited by mTOR inhibitor and PTEN overexpression.

CONCLUSIONS

Preoperative FIB could be related with the prognosis of PLC patients, the risk of death in PLC patients gradually increases along with the up-regulation of FIB. FIB may promote hepatoma metastasis by inducing EMT via the activation of PTEN/AKT/mTOR pathway.

摘要

目的

高纤维蛋白原血症在各类癌症患者中广泛存在,然而,纤维蛋白原(FIB)是否影响原发性肝癌(PLC)患者的生存结局仍不清楚。本研究旨在评估术前FIB对PLC患者生存结局的预测价值,并探讨其可能机制。

方法

对接受肝切除术的PLC患者进行回顾性研究。采用逻辑回归分析探讨PLC患者总生存(OS)的独立危险因素。通过Kaplan-Meier法、受试者工作特征曲线和Cox比例风险模型结合B样条分析FIB对生存结局的预测价值。采用伤口愈合试验和Transwell试验检测肝癌细胞迁移和侵袭能力,采用蛋白质印迹法检测蛋白表达。使用mTOR抑制剂和PTEN过表达质粒来证实PTEN/AKT/mTOR通路在FIB处理过程中的作用。

结果

术前FIB被证实与PLC患者的OS相关,较高的FIB(>2.5 g/L)表明更高的风险比。同时,FIB可通过激活AKT/mTOR通路和上皮-间质转化(EMT)促进肝癌细胞迁移和侵袭。此外,mTOR抑制剂和PTEN过表达可抑制FIB对细胞迁移和侵袭的促进作用。

结论

术前FIB可能与PLC患者的预后相关,PLC患者的死亡风险随FIB上调而逐渐增加。FIB可能通过激活PTEN/AKT/mTOR通路诱导EMT促进肝癌转移。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff01/10248116/510de506f741/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验